tradmap

VVOS Earnings Vivos Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$26 -$13 $0 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $9M $17M 2019 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$24M -$12M $0 2019 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$21 -$10 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $3M $7M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$8M -$4M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–18 of 18
Q2 20262026-06-30-0.812026-08-1410-Q
Q1 20262026-03-31-0.522026-05-2010-Q
FY 20252025-12-31-2.072026-04-1510-K
Q3 20252025-09-30-1.492025-11-1910-Q
Q2 20262025-06-30-1.002026-08-1410-Q
Q1 20262025-03-31-0.452026-05-2010-Q
FY 20252024-12-31-2.222026-04-1510-K
Q3 20252024-09-30-1.942025-11-1910-Q
Q2 20252024-06-30-2.062025-08-1910-Q
Q1 20252024-03-31-1.632025-05-1510-Q
FY 20242023-12-31-11.142025-03-3110-K
Q3 20242023-09-30-8.092024-11-1410-Q
Q2 20242023-06-30-6.402024-08-1410-Q
Q1 20242023-03-31-1.722024-05-1410-Q
FY 20232022-12-31-25.902024-03-2810-K
Q3 20232022-09-30-20.902023-11-1410-Q
Q2 20232022-06-30-0.582023-08-1610-Q
Q1 20232022-03-31-0.252023-06-0810-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.